Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

The story archive

Every discovery.
A little clearer.

Browse the collection, follow a topic, or find the story that sparked your curiosity.

14 published stories · Gene Therapy

13
Gene Therapy

Regenxbio Scores Pivotal Win for Duchenne Gene Therapy

Regenxbio has announced that its new gene therapy for Duchenne muscular dystrophy successfully met its main goal in a pivotal clinical trial. A pivotal trial is typically a late-stage study designed to gather the definitive evidence needed for government approval. For patients living with this severe muscle-wasting disease, passing this milestone is a critical step toward a potential new treatment. This success marks a dramatic turnaround for the biotechnology company. Before this positive news, Regenxbio had been struggling with severe regulatory roadblocks. The company recently faced a formal rejection from the Food and Drug Administration, as well as a clinical hold, which is an order that temporarily pauses medical research due to regulatory concerns. While the announcement is a clear victory for the company, important details are still missing. The initial reports do not provide specific numerical data, the size of the patient group studied, or the exact medical benchmarks the therapy achieved. Scientists and regulators will need to review the full data to fully understand the effectiveness of the treatment.

Fierce Biotech · 1 min read
14
Gene Therapy

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News · 1 min read